Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
3.
Int Immunopharmacol ; 8(6): 782-91, 2008 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-18442781

RESUMO

NOD mice are used as experimental models as they develop type 1 diabetes mellitus (DM-1) spontaneously, with a strong similarity to the human disease. Diabetes mellitus type 1 is characterized by the destruction of the islet, orchestrated by T lymphocytes that induce cytokine release like IL-1beta, promoting an inflammatory process. Diacerhein has antiinflammatory properties, inhibiting IL-1. However, the mechanisms involved in immune modulation are not completely understood. In the present study, serum and pancreatic islets were isolated to investigate the relationship between IL-1beta, IFN-gamma, IL-12 and TNF-alpha expression and diabetes onset, morphological aspects, and diacerhein dose dependence in animals treated with different doses (5, 10 and 50 mg/kg/day) and the control group (saline solution). The results demonstrated upregulation of mRNA islets and downregulation of the serum concentration of IL-1beta, IL-12 and TNF-alpha in the group treated with 5 and 10 mg/kg/day diacerhein, when compared with the saline group, and increased IFN-gamma serum concentration in the group treated with 50 mg/kg/day. These results suggest that diacerhein in NOD mice, decreases, in a dose-dependent manner, the diabetes frequency downregulating proinflammatory cytokines, such as IL-1beta, TNF-alpha, IFN-gamma and IL-12 at posttranscriptional or posttranslational level. Furthermore, using the HPLC method, diacerhein and rhein (active metabolite) were detected in serum and pancreas of treated mice.


Assuntos
Antraquinonas/farmacologia , Anti-Inflamatórios não Esteroides/farmacologia , Citocinas/metabolismo , Diabetes Mellitus Tipo 1/imunologia , Ilhotas Pancreáticas/imunologia , Animais , Antraquinonas/administração & dosagem , Anti-Inflamatórios não Esteroides/administração & dosagem , Citocinas/sangue , Diabetes Mellitus Tipo 1/metabolismo , Interferon gama/sangue , Interferon gama/efeitos dos fármacos , Interferon gama/metabolismo , Interleucina-1/sangue , Interleucina-1/metabolismo , Interleucina-12/sangue , Interleucina-12/metabolismo , Ilhotas Pancreáticas/efeitos dos fármacos , Camundongos , Camundongos Endogâmicos NOD , Fator de Necrose Tumoral alfa/sangue , Fator de Necrose Tumoral alfa/efeitos dos fármacos , Fator de Necrose Tumoral alfa/metabolismo
4.
Cytokine ; 42(1): 92-104, 2008 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-18329889

RESUMO

NOD (non-obese diabetic) mice develop type 1 diabetes mellitus spontaneously and with a strong similarity to the human disease. Differentiation and function of pancreas beta cells are regulated by a variety of hormones and growth factors, including the nerve growth factor (NGF). Gangliosides have multiple immunomodulatory activities with immunosuppressive properties, decreasing lymphoproliferative responses and modulating cytokine production. In the present study, serum, pancreas islets and spleen mononuclear cells from NOD mice treated with monosialic ganglioside GM1 (100 mg/kg/day) and the group control which received saline solution were isolated to investigate the proinflammatory cytokines (IL-1beta, IFN-gamma, IL-12, TNF-alpha), NGF and its high-affinity receptor TrkA, peri-islet Schwann cells components (GFAP, S100-beta) expression and the relationship with diabetes onset and morphological aspects. Our results suggest that GM1 administration to female NOD mice beginning at the 4th week of life is able to reduce the index of inflammatory infiltrate and consequently the expression of diabetes, modulating the expression of proinflammatory cytokines (IL-12, IFN-gamma, TNF-alpha and IL-1beta). Furthermore, GM1 increases GFAP, S-100beta and NGF in pancreas islets, factors involved in beta cell survival.


Assuntos
Citocinas/metabolismo , Diabetes Mellitus Tipo 1/imunologia , Gangliosídeo G(M1)/metabolismo , Camundongos Endogâmicos NOD , Fator de Crescimento Neural/metabolismo , Receptor trkA/metabolismo , Idade de Início , Animais , Citocinas/genética , Feminino , Gangliosídeo G(M1)/administração & dosagem , Proteína Glial Fibrilar Ácida , Humanos , Ilhotas Pancreáticas/citologia , Ilhotas Pancreáticas/metabolismo , Masculino , Camundongos , Fator de Crescimento Neural/genética , Fatores de Crescimento Neural/genética , Fatores de Crescimento Neural/metabolismo , Proteínas do Tecido Nervoso/genética , Proteínas do Tecido Nervoso/metabolismo , Receptor trkA/genética , Subunidade beta da Proteína Ligante de Cálcio S100 , Proteínas S100/genética , Proteínas S100/metabolismo , Células de Schwann/citologia , Células de Schwann/metabolismo , Baço/citologia , Baço/metabolismo
5.
Cytokine ; 36(3-4): 123-33, 2006 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-17188888

RESUMO

Two variants of this Walker 256 tumor have been previously reported as Walker 256 A and variant AR. The variant A has more aggressive property than variant AR and can induce systemic effects such as anorexia, sodium and water retention, followed by weight loss and death. The mechanisms involved in enhancing tumor regression and progression in this model are still incompletely understood. In the present study, serum and spleen mononuclear cells and tumor cells from animals inoculated with variants A and AR, were isolated to investigate the TGF-beta, IL-12, IFN-gamma and TNF-alpha and relationship with anemia, weight of animals, weight of spleen, volume of tumor and osmotic fragility compared with controls inoculated with Ringer Lactate. Results demonstrate that the group inoculated with variant A, compared to variant AR, shows high levels of TGF-beta gene expression in both tumor tissue and spleen cells, no expression of IFN-gamma and a progressive and higher levels of IL-12 in tumor tissue without inflammatory infiltrate visualized by optical microscopy. These results suggest that the aggressively of variant A is relate to cytokine modulation, facilitating the growth and escape of tumor cells. Furthermore, IL-12 seems to be constitutively expressed in both tumor lineage A and AR.


Assuntos
Carcinoma 256 de Walker/genética , Citocinas/genética , Anemia/sangue , Anemia/genética , Anemia/patologia , Animais , Peso Corporal , Carcinoma 256 de Walker/sangue , Carcinoma 256 de Walker/patologia , Citocinas/sangue , Ensaio de Imunoadsorção Enzimática , Expressão Gênica , Hemoglobinas/análise , Interferon gama/sangue , Interferon gama/genética , Interleucina-12/genética , Masculino , Tamanho do Órgão , Fragilidade Osmótica , RNA Mensageiro/genética , RNA Mensageiro/metabolismo , Ratos , Ratos Wistar , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Baço/metabolismo , Baço/patologia , Fator de Crescimento Transformador beta/sangue , Fator de Crescimento Transformador beta/genética , Fator de Necrose Tumoral alfa/genética
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA